Zonisamide was added to other medications up to the maximum dose of 300 mg and a longitudinal analysis was performed at 3 months and after a year. The 80% of the patients was under treatment with fluoxetine and there was not modification of the pharmacological treatment during the follow-up. The sample consisted of seventeen females patients: see description in Table 1 . Primary outcome measure was binging frequency. Secondary outcomes were Body Mass Index (BMI), Clinical Global Impressions-Severity of Illness Scale (CGI-SI) and self-injury. Ten of the seventeen patients concluded the 12 month follow-up; the other seven patients discontinued for the following reasons: increase of ocular pressure (n = 1), increase of serum creatinine levels (n = 1); paranoid symptoms (n = 1) and withdrawal of the follow-up (n = 4). Due to the little sample size only BMI and CGI-SI were analysed at endpoint visit. The statistical analysis evaluated treatment-by-time interaction effect on BMI, binging behaviour, self-harming and the CGI-SI. A 5.72% reduction of BMI (p = 0.02), a decrease in binges (p = 0.01) and self-harming episodes (p = 0.03) and a significant improvement in CGI-SI (p < 0.00001) were observed after 12 weeks of treatment. Improvement in CGI-SI was prolonged a year after (p < 0.00001), not the improvement of BMI (0.19). According to our review this is the first study that evaluates the efficacy of Zonisamide 1516-4446 -©2011 Elsevier Editora Ltda. All rights reserved.
Patients with eating disorders (ED) treated with Zonisamide
Pacientes com transtornos alimentares (TA) tratados com Zonisamida in subjects with BN: the most interesting observation was that Zonisamide was clinically effective to control self-injury. In addition, we found a significant correlation between axis II diagnose and self-harm indicating that Zonisamide is more efficacious on patients with border-line co-morbidity. It is reported that Zonisamide is effective for the long term treatment. 4 In our study the improvement of BMI found at endpoint visit was not significant: this fact might be attributable to the high attrition (35,3%) that we reported, comparable to the attrition rate reported in McElroy`s study. 5 As far as we know the increase of ocular pressure (most serious adverse event reported) has not been described in studies concerning Zonisamide's tolerability. To conclude we think that Zonisamide is useful for treating overweight in BED and BN patients and may be an option for controlling other impulsive behaviours in patients with ED.
